Sequential chemoimmunotherapy using mitomycin followed by bacillus Calmette-Guerin (MCC + BCG) versus single-agent immunotherapy (BCG) for recurrent superficial bladder tumors

UroToday International Journal

Volumn 3, Issue 3, 2010, Pages

  Mohsen, Mostafa Abd El ^a   Shelbaia, Ahmed ^a   Ghobashy, Samir El ^b   Swellam, Tarek ^b   Ganzoury, Hosam El ^b   Ali, Mohammed ^b   Leithy, Tarek El ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Egypt   (Egypt)

Author keywords

BCG; Bladder cancer; MMC; Sequential chemoimmunotherapy

Indexed keywords

EID: 77954420577     PISSN: None     EISSN: 19394810     Source Type: Journal    
DOI: 10.3834/uij.1944-5784.2010.06.06     Document Type: Article

References (18)

1. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer, progression and recurrence. J Urol. 1983;130(6):1083-1086.
2. Herr HW, Jakse J, Sheinfeld J. The T1 bladder tumor. Semin Urol. 1990;8(4):254-261.
3. Kim JC, Steinberg GD. The limits of bacillus Calmette- Guerin for carcinoma in situ of the bladder. J Urol. 2001;165(3):745-756.
4. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol. 1996;156(1):56-60.
5. Soloway MS. Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. J Urol. 1985;134(6):1107-1109
6. Jauhiainen K. and Alfthan O. Instillation of mitomycin C and doxorubicin in prevention of recurrent superficial (Ta- T1) bladder cancer. Br J Urol. 1987;60(1):54-59.
7. Huland H, Kloppel G, Feddersen I, et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol. 1990;144(1):68-72.
8. Sarosdy MF, Lamm DL. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1989;142(3):719-722.
9. Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L Jr., et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990;143(3):502-506.
10. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205-1209.
11. Herr HW, Laudone VP, Badalament RA, et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 1988;6(9):1450-1455.
12. Rintala E, Jauhiainen K, Alfthan O. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer. Eur Urol. 1991;20(1):19-25.
13. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163(1):73-78.
14. Colombo R, Da Pozzo LF, Salonia A. et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21(23):4270-4276.
15. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7(1):43-51.
16. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage Ta Ti bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical research Council Working Party on Superficial Bladder Cancer. J Urol. 1996;156(6):1934-1941.
17. Tolley DA, Hargreave TB, Smith PH, et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J (Clin Res Ed). 1988;296(6639):1759-1761.
18. Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, van der Meijden AP. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol. 1995;153(3 Pt 2):929-933.